Skip to main content

Month: June 2024

Norsk Hydro ASA: Registration of share capital reduction

Reference is made to the stock exchange notice by Norsk Hydro ASA (“Hydro”) on May 7, 2024, regarding inter alia the resolution by the annual general meeting to reduce Hydro’s share capital by NOK 35,347,500.054 by cancellation of 21,163,019 own shares and by redemption and cancellation of 11,029,604 shares held by the Norwegian state. The share capital reduction has now been registered with the Norwegian Register of Business Enterprises. After this, Hydro’s new registered share capital is NOK 2,205,899,565.804, divided on a total of 2,009,015,998 shares, each with a nominal value of NOK 1.098.  Investor contact: Martine Rambøl Hagen +47 91708918 Martine.Rambol.Hagen@hydro.com  Media contact: Halvor Molland +47 92979797 Halvor.Molland@hydro.com This information is subject to the disclosure requirements pursuant...

Continue reading

Effnet 5G gNB-CU validated using VIAVI TeraVM and power monitoring for Red Hat OpenShift for energy efficient computing

Luleå 2024-06-25 – Effnet, a leading provider of containerized 5G RAN software and 5G protocol stack for terminals as well as Header Compression software, today announces its successful participation in interoperability testing together with VIAVI and Red Hat. Effnet 5G gNB-CU is a scalable, disaggregated (gNB-CU CP and gNB-CU UP), containerized and platform agnostic software solution. Its support for Red Hat OpenShift, the industry’s leading hybrid cloud application platform powered by Kubernetes, provides the telco industry with another trusted option to consider when building high-performance network functions in containerized environments. Effnet 5G gNB-CU, running on Red Hat OpenShift, was validated for conformance and interoperability using VIAVI TeraVM, a virtualized application emulation and security performance platform, used...

Continue reading

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion

Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS; THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S....

Continue reading

Rogers offers Disney+ to Rogers TV customers at no additional cost

Gives customers thousands of hours of exclusive shows and movies as part of their TV package TORONTO, June 25, 2024 (GLOBE NEWSWIRE) — Rogers Communications and Disney Entertainment announced today that the ad-supported version of Disney+ is now available to Rogers TV customers at no additional cost. As the home of sports and entertainment in Canada, this agreement brings Rogers video subscribers the best of TV and the iconic originals and classics from Disney+ together in one package. “We want to deliver more value to our customers and create a more seamless viewing experience,” said Bret Leech, President, Residential Services, Rogers. “By integrating Disney+, we’re adding even more value to our entertainment packages and making it easier than ever for customers to enjoy the shows and movies they love.” “Rogers is one of our most...

Continue reading

CORRECTION: Capricor Therapeutics

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) — In a release issued under the headline “Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy” on Tuesday, June 25th by Capricor Therapeutics, please note that the words “Pre-BLA Meeting with FDA for Deramiocel” were omitted from the headline. The corrected release follows. Capricor Therapeutics Announces Pre-BLA Meeting with FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre-BLA (Biologics License Application) meeting with the Company in the third quarter of 2024 for deramiocel (CAP-1002),...

Continue reading

Exploration Drilling at Becher Project Recommences

HIGHLIGHTSFollow-up aircore (AC) and reverse circulation (RC) drilling programs have been commenced by De Grey Mining (De Grey) at Novo’s flagship Becher Project (Becher), using two drill rigs. The focus is on testing gold and base metal mineralisation at the priority Heckmair and Lowe Prospects.Becher is part of the Egina Joint Venture, where major ASX-listed Western Australian gold explorer and developer De Grey is earning-in through a minimum spend of A$7 million to December 2024, as part of a required A$25 million spend over 4 years to earn 50% of the joint venture. De Grey is the manager of the Egina Joint Venture.Becher lies adjacent to De Grey’s 12.7 Moz1 Hemi Gold Project.Exploration completed to date by Novo and De Grey at Becher has identified both intrusion-hosted and structurally controlled gold mineralisation similar...

Continue reading

The Supreme Court partially satisfied the cassation of Tallinn University of Technology

Today, the Supreme Court made a judgment by which annulled the decisions made by the lower courts in this case and sent the case back to the same county court for a new review. The Supreme Court accused the lower courts of erroneously taking the view that the plaintiff’s claim was not justified under the damage’s provisions. The Supreme Court found that after the entry into force of the Public Water Supply and Sewerage Act (ÜVVKS) (01/10/2010), AS Tallinna Vesi should have established a price that meets the criteria of § 14 (2) of the ÜVVKS within a reasonable time. During the re-examination of the case, the county court must assess what is a reasonable time to establish a price in accordance with the law. In addition, the county court must assess whether the water price applications submitted by AS Tallinna Vesi to the Competition...

Continue reading

UPDATE — Faircourt Asset Management Inc. Announces June Distribution

TORONTO, June 25, 2024 (GLOBE NEWSWIRE) — Faircourt Asset Management Inc., as Manager of the Faircourt Fund (NEO:FGX), is pleased to announce the monthly distribution payable on the Shares of the below listed Fund.Faircourt Funds Trading Symbol Distribution Amount (per share/unit) Ex-Dividend Date Record Date Payable DateFaircourt Gold Income Corp. FGX $0.024 June 27, 2024 June 28, 2024 July 15, 2024           Faircourt Asset Management Inc. is the Investment Advisor for Faircourt Gold Income Corp. This press release is not for distribution in the United States or over United States wire services. For further information on the Faircourt Funds, please visit www.faircourtassetmgt.com or please contact 1-800-831-0304. You will usually pay brokerage fees to your dealer if you purchase or sell Shares of the Fund on the...

Continue reading

Devon Energy Schedules Second-Quarter 2024 Earnings Release and Conference Call

OKLAHOMA CITY, June 25, 2024 (GLOBE NEWSWIRE) — Devon Energy Corp. (NYSE: DVN) today announced it will report second-quarter 2024 results on Tuesday, Aug. 6, after the close of U.S. financial markets. The earnings release and presentation for the second-quarter 2024 results will be available on the company’s website at www.devonenergy.com. On Wednesday, Aug. 7, the company will hold a conference call at 10:00 a.m. Central Time (11:00 a.m. Eastern Time), which will consist primarily of answers to questions from analysts and investors. A webcast link to the conference call will be provided on Devon’s website at www.devonenergy.com. A replay will be available on the website following the call. ABOUT DEVON ENERGY Devon Energy is a leading oil and gas producer in the U.S. with a premier multi-basin portfolio headlined by a world-class...

Continue reading

Pressure BioSciences Partners with Vita-Forte, Largest Global Supplier of Freeze-Dried Acai, to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral Spray

Processed by PBIO’s Patented UltraShear Technology, this Revolutionary Product Combines Leading Potency Oil-Based Antioxidants (e.g., Acai, Curcumin, Astaxanthin, CoQ10, & More) into a Super-Fast Absorbing, Highly Bioavailable, Nanoemulsified Oral Spray for Market-Leading Performance CANTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today announced a partnership with Vita-Forte, the largest distributor in the world of freeze-dried Acai (a potent antioxidant) to develop a highly...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.